CN114555053B - 治疗乳腺癌的方法 - Google Patents

治疗乳腺癌的方法

Info

Publication number
CN114555053B
CN114555053B CN202080071066.3A CN202080071066A CN114555053B CN 114555053 B CN114555053 B CN 114555053B CN 202080071066 A CN202080071066 A CN 202080071066A CN 114555053 B CN114555053 B CN 114555053B
Authority
CN
China
Prior art keywords
dapam
shu jing
breast cancer
mice
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080071066.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN114555053A (zh
Inventor
查尔斯·A·迪纳雷罗
伊萨克·滕格斯达尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oratec Treatment Co
Olatec Therapeutics Inc
Original Assignee
Oratec Treatment Co
Olatec Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oratec Treatment Co, Olatec Therapeutics Inc filed Critical Oratec Treatment Co
Publication of CN114555053A publication Critical patent/CN114555053A/zh
Application granted granted Critical
Publication of CN114555053B publication Critical patent/CN114555053B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CN202080071066.3A 2019-10-14 2020-10-12 治疗乳腺癌的方法 Active CN114555053B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962914833P 2019-10-14 2019-10-14
US62/914,833 2019-10-14
PCT/US2020/055219 WO2021076444A1 (en) 2019-10-14 2020-10-12 Methods for treating breast cancer

Publications (2)

Publication Number Publication Date
CN114555053A CN114555053A (zh) 2022-05-27
CN114555053B true CN114555053B (zh) 2025-09-30

Family

ID=75538857

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080071066.3A Active CN114555053B (zh) 2019-10-14 2020-10-12 治疗乳腺癌的方法

Country Status (6)

Country Link
US (1) US12582628B2 (https=)
EP (1) EP4045009A4 (https=)
JP (1) JP2022551672A (https=)
CN (1) CN114555053B (https=)
AU (1) AU2020366300A1 (https=)
WO (1) WO2021076444A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025501657A (ja) * 2022-01-10 2025-01-22 オラテック セラピューティクス， インコーポレイティド 膵臓がんを治療するための方法
CN119744351A (zh) * 2022-03-02 2025-04-01 欧拉泰克治疗公司 用于治疗患有潜能未定的克隆性造血的实体癌患者的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019182981A1 (en) * 2018-03-21 2019-09-26 Olatec Therapeutics Llc Methods for treating melanoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2651407B1 (en) 2010-12-15 2016-12-21 Olatec Industries LLC 3-methanesulfonylpropionitrile for treating inflammation and pain
PL2914264T3 (pl) * 2012-11-02 2017-12-29 Merck Patent Gmbh Pochodna 6-okso-1,6-dihydropirydazyny do zastosowania w leczeniu raka wątrobowokomórkowego (hcc)
PE20170255A1 (es) * 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
EP3589370A4 (en) * 2017-01-06 2020-11-18 Olatec Therapeutics LLC MULTIPLE SCLEROSIS TREATMENT METHOD
ES2970485T3 (es) 2017-01-06 2024-05-29 Olatec Therapeutics Llc Composición farmacéutica para su uso en el tratamiento de enfermedades cardiovasculares
WO2019032672A1 (en) * 2017-08-11 2019-02-14 Olatec Therapeutics Llc METHOD OF TREATING SCHNITZLER SYNDROME
CA3087865A1 (en) * 2018-01-31 2019-08-08 Olatec Therapeutics Llc Method for preventing or treating alzheimer's disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019182981A1 (en) * 2018-03-21 2019-09-26 Olatec Therapeutics Llc Methods for treating melanoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Blocking IL-1β reverses the immunosuppression inmouse breast cancer and synergizes with anti–PD-1for tumor abrogation;Irena Kaplanov;《Proc. Natl. Acad. Sci. U.S.A.》;20190122;第116卷(第4期);第1361-1369页 *

Also Published As

Publication number Publication date
US20220249425A1 (en) 2022-08-11
CN114555053A (zh) 2022-05-27
JP2022551672A (ja) 2022-12-12
WO2021076444A1 (en) 2021-04-22
AU2020366300A1 (en) 2022-06-02
EP4045009A4 (en) 2023-11-01
EP4045009A1 (en) 2022-08-24
US12582628B2 (en) 2026-03-24

Similar Documents

Publication Publication Date Title
EP2684569A1 (en) A composition for treatment of advanced prostate cancer
EP2471548A1 (de) siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs
CN114555053B (zh) 治疗乳腺癌的方法
US11857529B2 (en) Methods for treating melanoma
JP2848922B2 (ja) 胸膜の原発癌を治療する意図の薬剤組成物を製造するためのヒトインターロイキン２の活性を有するポリペプチドの使用
EP3664786B1 (en) Method for treating schnitzler's syndrome
AU2012238523B2 (en) Drug containing recombinant mistletoe lectins for treating malignant melanoma
EP4536647A1 (en) Novel ras inhibitors
CN113905764A (zh) 用于治疗癌症的前体半胱天冬酶-3活化作用和免疫疗法
Brown et al. Interferons and bladder cancer
US20240417812A1 (en) Methods for treating solid cancer patients with clonal hematopoiesis of indeterminate potential
US20240358669A1 (en) Methods for treating pancreatic cancer
EP4536665A1 (en) Novel ras inhibitors
WO2023242106A1 (en) Novel ras inhibitors
EP4536641A1 (en) Novel ras inhibitors
AU2023293888A1 (en) Mitoxanthrone derivatives as ras inhibitors
EP4536203A1 (en) Diaminoacridine derivatives as inhibitors of ras
EP4654961A1 (en) Novel mixtures as ras inhibitors for use in the treatment of proliferative and genetic diseases
Eisenhrand I Drug Development in Oncology
HK1193755A (en) A composition for treatment of advanced prostate cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: USA New York

Applicant after: Oratec Treatment Co.

Address before: USA New York

Applicant before: OLATEC INDUSTRIES LLC

Country or region before: U.S.A.

GR01 Patent grant
GR01 Patent grant